Voloridge Investment Management, LLC Inhibrx, Inc. Transaction History

Voloridge Investment Management, LLC

  • $26.2 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$15.75 - $26.31 $168,682 - $281,780
10,710 New
10,710 $196,000
Q1 2023

May 15, 2023
SELL
$18.45 - $27.14 $1.35 Million - $1.98 Million
-72,965 Reduced 44.2%
92,107 $1.74 Million
Q4 2022

Feb 14, 2023
BUY
$20.18 - $33.33 $3.33 Million - $5.5 Million
165,072 New
165,072 $4.07 Million
Q2 2022

Aug 15, 2022
SELL
$8.52 - $25.26 $268,090 - $794,831
-31,466 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$19.89 - $43.18 $625,858 - $1.36 Million
31,466 New
31,466 $701,000

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email